Abacus Bioscience Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$4.41M
- Investors
-
8
Abacus Bioscience General Information
Description
Developer of novel immune therapeutic treatments intended to assist in treating cancer and chronic viral diseases. The company's treatments are based upon the delivery of antigens capable of evoking protective immunity to a receptor expressed just on two major classes of cells that program immune responses, enabling medical professionals with a broad-based platform that can plug and play with multiple cancer or viral antigens.
Contact Information
Website
www.abacusbioscience.comCorporate Office
- 1616 Eastlake Avenue East
- Unit 208
- Seattle, WA 98102
- United States
Corporate Office
- 1616 Eastlake Avenue East
- Unit 208
- Seattle, WA 98102
- United States
Abacus Bioscience Timeline
Abacus Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A) | 07-Feb-2023 | $4.41M | Completed | Pre-Clinical Trials | ||
| 2. Grant | 01-Jun-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 06-Feb-2019 | $150K | $150K | Completed | Generating Revenue |
Abacus Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-4 | ||||||||
| Seed-3 | ||||||||
| Seed-2 | 348,902 | $0.001000 | $0.56 | $0.56 | 1x | $0.56 | 1.76% | |
| Seed-1 | 4,633,307 | $0.001000 | $0.76 | $0.76 | 1x | $0.76 | 23.33% |
Abacus Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Abacus Bioscience Patents
Abacus Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230053634-A1 | Therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein | Pending | 16-Nov-2017 | ||
| US-11389532-B2 | Therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein | Active | 16-Nov-2017 | ||
| US-20200345838-A1 | A therapeutic vaccine for hepatitis b virus (hbv) using the hbv pres1 and/or pres2, and/or s-hbsag regions of the hbv envelope protein | Active | 16-Nov-2017 | ||
| US-20200306367-A1 | Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen | Active | 06-Apr-2016 | ||
| US-11324819-B2 | Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen | Active | 06-Apr-2016 | C07K14/005 |
Abacus Bioscience Executive Team (5)
| Name | Title | Board Seat |
|---|---|---|
| Alan Wahl Ph.D | Co-Founder, Chief Executive Officer & Board Member | |
| Che-Leung Law Ph.D | Co-Founder, Chief Scientific Officer & Board Member | |
| Craig Philips | Co-Founder | |
| Raj Dua Ph.D | Co-Founder | |
| Edward Clark Ph.D | Co-Founder, Scientific Advisor Board & Chairman |
Abacus Bioscience Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Wahl Ph.D | Abacus Bioscience | Co-Founder, Chief Executive Officer & Board Member | |
| Che-Leung Law Ph.D | Abacus Bioscience | Co-Founder, Chief Scientific Officer & Board Member | |
| Diane Hollenbaugh | Self | Board Member | |
| Edward Clark Ph.D | Abacus Bioscience | Co-Founder, Scientific Advisor Board & Chairman | |
| Jonathan Drachman | Self | Board Member |
Abacus Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Abacus Bioscience Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Alliance of Angels | Angel Group | Minority | ||
| Pack Ventures | Venture Capital | Minority | ||
| Sahsen Ventures | Venture Capital | Minority | ||
| Seagen | Corporation | Minority |
Abacus Bioscience FAQs
-
When was Abacus Bioscience founded?
Abacus Bioscience was founded in 2015.
-
Who is the founder of Abacus Bioscience?
Alan Wahl Ph.D, Che-Leung Law Ph.D, Craig Philips, Raj Dua Ph.D, and Edward Clark Ph.D are the founders of Abacus Bioscience.
-
Who is the CEO of Abacus Bioscience?
Alan Wahl Ph.D is the CEO of Abacus Bioscience.
-
Where is Abacus Bioscience headquartered?
Abacus Bioscience is headquartered in Seattle, WA.
-
What is the size of Abacus Bioscience?
Abacus Bioscience has 9 total employees.
-
What industry is Abacus Bioscience in?
Abacus Bioscience’s primary industry is Drug Discovery.
-
Is Abacus Bioscience a private or public company?
Abacus Bioscience is a Private company.
-
What is the current valuation of Abacus Bioscience?
The current valuation of Abacus Bioscience is .
-
What is Abacus Bioscience’s current revenue?
The current revenue for Abacus Bioscience is .
-
How much funding has Abacus Bioscience raised over time?
Abacus Bioscience has raised $4.56M.
-
Who are Abacus Bioscience’s investors?
Alexandria Venture Investments, Alliance of Angels, Pack Ventures, Sahsen Ventures, and Seagen are 5 of 8 investors who have invested in Abacus Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
